Lexicon Pharmaceuticals (LXRX) Downgraded by JPMorgan Chase & Co.

JPMorgan Chase & Co. downgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a neutral rating to an underweight rating in a report issued on Wednesday, MarketBeat Ratings reports. They currently have $10.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $15.00.

Other equities analysts have also recently issued reports about the stock. BidaskClub upgraded shares of Lexicon Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, January 30th. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, November 14th. Wedbush restated an outperform rating and set a $38.00 price target on shares of Lexicon Pharmaceuticals in a report on Thursday, November 30th. Finally, ValuEngine cut shares of Lexicon Pharmaceuticals from a sell rating to a strong sell rating in a report on Friday, February 2nd. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $24.80.

Lexicon Pharmaceuticals (LXRX) opened at $7.86 on Wednesday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.65 and a current ratio of 1.66. Lexicon Pharmaceuticals has a fifty-two week low of $7.80 and a fifty-two week high of $18.00.

Several institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its holdings in Lexicon Pharmaceuticals by 17.9% in the second quarter. Goldman Sachs Group Inc. now owns 134,043 shares of the biopharmaceutical company’s stock worth $2,205,000 after purchasing an additional 20,379 shares in the last quarter. Kornitzer Capital Management Inc. KS bought a new stake in Lexicon Pharmaceuticals in the third quarter worth $9,420,000. Wells Fargo & Company MN boosted its holdings in Lexicon Pharmaceuticals by 27.2% in the third quarter. Wells Fargo & Company MN now owns 112,721 shares of the biopharmaceutical company’s stock worth $1,385,000 after purchasing an additional 24,131 shares in the last quarter. GSA Capital Partners LLP boosted its holdings in Lexicon Pharmaceuticals by 158.0% in the third quarter. GSA Capital Partners LLP now owns 50,786 shares of the biopharmaceutical company’s stock worth $624,000 after purchasing an additional 31,100 shares in the last quarter. Finally, Ameriprise Financial Inc. bought a new stake in Lexicon Pharmaceuticals in the second quarter worth $1,261,000.

COPYRIGHT VIOLATION NOTICE: “Lexicon Pharmaceuticals (LXRX) Downgraded by JPMorgan Chase & Co.” was first reported by Week Herald and is the property of of Week Herald. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://weekherald.com/2018/02/17/lexicon-pharmaceuticals-lxrx-downgraded-by-jpmorgan-chase-co.html.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply